title: Concerns regarding BRAF testing algorithm: reply from authors.
authors.affiliation: Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5NG, U.K.
authors.forename: D
authors.initials: D
authors.lastname: Gonzalez
authors.forename: L
authors.initials: L
authors.lastname: Fearfield
authors.forename: P
authors.initials: P
authors.lastname: Nathan
authors.forename: P
authors.initials: P
authors.lastname: Tanière
authors.forename: A
authors.initials: A
authors.lastname: Wallace
authors.forename: E
authors.initials: E
authors.lastname: Brown
authors.forename: C
authors.initials: C
authors.lastname: Harwood
authors.forename: J
authors.initials: J
authors.lastname: Marsden
authors.forename: S
authors.initials: S
authors.lastname: Whittaker
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D009154:Mutation / Q000235:genetics*; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D012878:Skin Neoplasms / Q000188:drug therapy*; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D048493:Proto-Oncogene Proteins B-raf